Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 361 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ARC Clear all
Completed Phase 2 Interventional

A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease

NCT00002110
View directory record Official record
Conditions
HIV Infections
Interventions
Cysteamine, Zidovudine
Drug
Lead sponsor
Mylan Laboratories
Industry
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Tampa, Florida • New Orleans, Louisiana • Stony Brook, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Results available

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
SL-279252
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

NCT00002124
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
87
States / cities
Birmingham, Alabama • Berkeley, California • Clovis, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional

Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

NCT00002238
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon beta-1b, Zidovudine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Berkeley, California • Los Angeles, California • Oakland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional

Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)

NCT00002063
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

NCT05828108
View directory record Official record
Conditions
Steroid-refractory Diamond-Blackfan Anemia (DBA)
Interventions
Bitopertin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Recruiting Not applicable Interventional

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

NCT06572423
View directory record Official record
Conditions
Head and Neck Carcinoma, Localized Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma
Interventions
Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Best Practice, University of Washington Quality of Life Scale, Version 4, Functional Assessment of Cancer Therapy-Head & Neck
Procedure · Radiation · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional

Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC

NCT00002020
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Tucson, Arizona • Chicago, Illinois • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients

NCT00002107
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

NCT00002111
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

NCT00000999
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 4:30 PM EDT
Suspended Phase 1 Interventional

68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma

NCT07353229
View directory record Official record
Conditions
High Risk Meningioma, Recurrent Meningioma
Interventions
⁶⁸Ga-Dotatate PET and MRI Guided Radiation Therapy, Magnetic Resonance Imaging (MRI), 68Ga-Dotatate PET Imaging, MD Anderson Symptom Inventory Bain Tumor form (MDASI-BT), EuroQol-5 Dimension (ED-5D)
Radiation · Diagnostic Test · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

NCT00000822
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine, Didanosine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Early Phase 1 Interventional

Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

NCT03162731
View directory record Official record
Conditions
Larynx, Lip, Oral Cavity and Pharynx
Interventions
Nivolumab, Ipilimumab, Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy
Biological · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

Phase I/II Study of Curdlan Sulfate

NCT00002100
View directory record Official record
Conditions
HIV Infections
Interventions
Curdlan sulfate
Drug
Lead sponsor
AJI Pharma USA
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Withdrawn Phase 2 Interventional

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

NCT03541486
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Ascorbate, Gemcitabine, radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors

NCT00001073
View directory record Official record
Conditions
HIV Infections, Cervix, Dysplasia
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional

The Up-LIFT Study of Non-Invasive ARC Therapy for Spinal Cord Injury

NCT04697472
View directory record Official record
Conditions
Chronic Spinal Cord Injury
Interventions
LIFT System
Device
Lead sponsor
ONWARD Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Englewood, Colorado • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 2 Interventional

A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT

NCT00001032
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
44
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

NCT00000744
View directory record Official record
Conditions
Candidiasis, Candidiasis, Esophageal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants

NCT04532164
View directory record Official record
Conditions
Dermatitis, Photoallergic
Interventions
Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 2 Interventional

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

NCT00002265
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Fort Lauderdale, Florida • Fort Myers, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers

NCT00000808
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 60 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 4:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)

NCT04614324
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
RhinAer ARC Stylus
Device
Lead sponsor
Aerin Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
12
States / cities
Goodyear, Arizona • Roseville, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 17, 2026, 4:30 PM EDT